A list of recent research advances in cell journal for the new coronavirus SARS-CoV-2/COVID-19 (No. 6)

paper co-author Dr. Thirumala-Devi Kanneganti, deputy director of the Department of Immunology at St. Jude Children's Research Hospital, said, "Understanding the path factors and mechanisms that drive this inflammation is critical to developing effective treatment strategies."
study provides this understanding.
we have also identified specific cytokines that activate the pathways of inflammatory cell death and have considerable potential for the treatment of COVID-19 and other highly fatal diseases, including sepsis.
"3.Cell: Assessing the effects of SARS-CoV-2 tingling protein mutation D614G on propagation and pathogenicity doi:10.1016/j.cell.2020.20 11.020 In a new study, researchers from research institutions such as Cardiff University, the University of Edinburgh and Imperial College of Technology assessed more than 25,000 SARS-CoV-2 genome-wide sequences collected in the UK between January and June.
as elsewhere, the 614G became the dominant variant in the UK in late March, and the 614G variant was introduced independently several times, mostly from people who had travelled internationally.
also confirmed that 614G was not related to the severity of the infection and observed that younger patients were more likely to be infected with 614G and had higher viral loads.
their findings support the idea that 614G is a positive choice and is likely to affect the spread of the virus.
results were published online November 18, 2020 in the journal Cell under the title "Evaluating the effects of SARS-CoV-2 Spike D614G on transmissibility and pathogenicity."
even with this huge data set, we have almost pushed the limits of our ability to identify the presence of this effect," Thomas Connor, a genetic epidemiologist at cardiff University in the UK and co-author of the paper, told The Scientist.
if the sample size is small, it will be more difficult to detect such small contagious changes," he said.
4.Cell: Chinese scientists have revealed that the transcription of the new coronavirus replication transcription complex of the cryogenic electroscope structure doi:10.1016/j.cell.2020.11.016SARS-CoV-2 mRNA requires a series of reactions facilitated by the replication transcription complex (replication and transcription complex, RTC).
a new study, researchers from Tsinghua University, Shanghai University of Science and Technology and Wuhan University in China showed a snapshot of the structure during the transition from SARS-CoV-2 RTC to cap structural synthesis.
they analyzed an extended RTC cryogenic mirror structure assembled from nsp7-nsp82-nsp12-nsp132-RNA and a single RNA binding protein, known as nsp9.
results were published online November 14, 2020 in the journal Cell under the title "Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Complex Reveals an Intermediate State in Cap Synthesis."
5.Cell: Barrettinib reduces inflammation in rhesus monkeys infected with the new coronavirus: 10.1016/j.cell.2020.11.007SARS-CoV-2-induced hypercytokinemia (hypercytokinemia) and inflammation are closely related to the severity of COVID-19 disease.
as a clinically approved JAK1/2 inhibitor, baricitinib is currently being studied in COVID-19 clinical trials.
a new study, researchers from Emory University in the United States studied the immunological and virological efficacy of Barrettinib in the sars-CoV-2-infected rhesus monkey model.
model simulates inflammatory characteristics observed in PATIENT-19 patients.
results were published online November 9, 2020 in the journal Cell under the title "Baricitinib treatment resolves lower airway macrophage and neutrophil search in SARS-CoV-2-infected rhesus macaques".
from Cell, 2020, doi:10.1016/j.cell.2020.11.007.
the virus shedding measured from nasal swabs, throat swabs, bronchopulmonal blisters and tissues did not decrease as a result of the use of barriteni.
, barrettinib inhibits the production of inflammatory cytokines in macrophages in the lungs.
type I IFN antiviral response and SARS-CoV-2 specific T-cell response were similar in two groups of rhesus monkeys treated with barriteni.
rhesus monkeys treated with barrettinib showed reduced inflammation, reduced inoculation of inflammatory cells in the lungs, reduced neural granulocyte capture network (NETosis) activity, and more limited lung pathology.
showed that in rhesus monkeys treated with barrettinib, the drug maintained a congenital antiviral response and a SARS-CoV-2-specific T-cell response.
6.Cell: Explain a magical case! A female leukemia patient infected with the new coronavirus at least 70 days after still shed infectious virus particles doi:10.1016/j.cell.2020.10.049 Most people infected with SARS-CoV-2 coronavirus appear to be active in about 8 days to shed the infectious virus, but the differences between people are very large.
important to understand how long people can remain active in infection because it provides new details about a disease and virus that is still not well understood, which helps guide public health decision-making.
In a new study, researchers from research institutions such as the National Institutes of Health (NIH), Marshall University and oxford University in the United Kingdom reported an unusual case in which a woman with leukemia and a low antibody count was infected with the coronavirus for at least 105 days and remained contagious for at least 70 days, but she remained asymptomatic throughout the process.
results were published online November 4, 2020 in the journal Cell under the title "Case Study: Prolonged association SARS-CoV-2 Shedding from an asymptomatic immunocompromised cancer patient."
co-author of the paper, The United States